glp 1 from china Ozempic craze hits as first GLP-1 weight-loss drug is greenlighted – The China Project Pfizer challenges Novo and Lilly:

More employers are voluntarily covering weight loss medications to recruit and retain talent

Medicare Data (2025): Once-weekly GLP-1 RAs (especially semaglutide) showed superior MACE reduction compared to SGLT2 inhibitors in Medicare beneficiaries with atherosclerotic cardiovascular disease (ASCVD)

When starting semaglutide, injection tracking and side effect logging are very important

Improved Satiety: By promoting the feeling of fullness, GLP-1 medications can help women avoid overeating, especially when dealing with heightened hunger due to hormonal changes

GLP-1 is an incretin hormone produced by intestinal L-cells that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety in response to food intake

Looking forward, future research should focus on long-term safety, durability of weight loss, and real-world effectiveness of GLP-1RAs across diverse populations, including those in LMICs